Resveratrol administration also increases the sensitivity of oral squamous cell carcinoma to cetuximab by decreasing the protein expression of uPAR, which inhibits the signaling molecule ERK1/2 downstream of EGFR [828]. This evidence concerns the gene MAPK3 and oral cavity squamous cell carcinoma.